<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), including <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> and <z:hpo ids='HP_0001924'>sideroblastic anemia</z:hpo>, are characterized by increased apoptotic <z:hpo ids='HP_0011420'>death</z:hpo> of erythroid progenitors </plain></SENT>
<SENT sid="1" pm="."><plain>The signaling pathways that elicit this pathologic cell <z:hpo ids='HP_0011420'>death</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> have, however, remained unclear </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment with erythropoietin in combination with granulocyte colony-stimulating factor (G-CSF) may synergistically improve the <z:hpo ids='HP_0001903'>anemia</z:hpo> in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, with a concomitant decrease in the number of apoptotic bone marrow precursors </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, we have previously reported that G-CSF inhibits Fas-induced caspase activation in <z:hpo ids='HP_0001924'>sideroblastic anemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>The present data demonstrate that almost 50% of erythroid progenitor cells derived from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> exhibit spontaneous release of <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> from mitochondria with ensuing activation of caspase-9, whereas <z:mpath ids='MPATH_458'>normal</z:mpath> erythroid progenitors display neither of these features </plain></SENT>
<SENT sid="5" pm="."><plain>G-CSF significantly inhibited <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> release and suppressed <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, most noticeably in cells from patients with <z:hpo ids='HP_0001924'>sideroblastic anemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, inhibition of caspase-9 suppressed both spontaneous and Fas-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of erythroid progenitors in <z:hpo ids='HP_0000001'>all</z:hpo> low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases studied </plain></SENT>
<SENT sid="7" pm="."><plain>We propose that the increased sensitivity of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progenitor cells to <z:hpo ids='HP_0011420'>death</z:hpo> receptor stimulation is due to a constitutive activation of the <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> axis of the apoptotic signaling pathway in these cells </plain></SENT>
<SENT sid="8" pm="."><plain>These studies yield a mechanistic explanation for the beneficial clinical effects of growth factor administration in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and provide a model for the study of growth factor-mediated suppression of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in other <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">bone marrow disorders</z:e> </plain></SENT>
</text></document>